Associated Papers
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
39876053 (PubMed )
Supplement: supplement_1.pdf
Mutational Damages in Malignant Lung Tumors.
Yermekova S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2022
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA et al.
Plos One, 2022
35294956 (PubMed )
Supplement: pone.0264138.s001.docx
Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P et al.
Scientific Reports, 2021
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K et al.
Cancer Research and Treatment, 2020
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y et al.
Journal for Immunotherapy of Cancer, 2019
30944026 (PubMed )
Supplement: 40425_2019_581_MOESM3_ESM.pdf
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD et al.
Jama Oncology, 2018
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Bailey MH et al.
Cell, 2018
Select a paper to view details